Loading...
Nontuberculous mycobacteria (NTM) are increasingly recognized in causing respiratory and soft-tissue infections — moreover, Mycobacteroides abscessus (previously Mycobacterium abscessus) may be exceptionally challenging due to its intrinsic antibiotic resistance. The novel aminomethylcycline known as omadacycline (OMC; approved in both intravenous [IV] and oral formulations for skin infections and pneumonia) has been increasingly relied upon to treat NTM based on susceptibility, but clinical data are lacking.
In a retrospective observational study across 16 U.S. centers from January 2020 through March 2023, researchers assessed clinical success, safety, and tolerability in 75 patients (64% female, 77% Caucasian; median age, 59) receiving OMC…